Precigen (PGEN) investor relations material

Executive summary

• PAPZIMEOS, approved in August 2025 as the first and only FDA-approved therapy for adults with RRP, achieved a landmark first commercial launch and is now the primary revenue driver, with rapid adoption across major medical centers and community practices.

• Transitioned from a development-stage to a commercial-stage company, supported by strong payer coverage and a permanent J-code.

• A landmark expert position paper and robust clinical data have established PAPZIMEOS as the new standard of care.

• Patient hub enrollment reached approximately 400, with 25% from community settings, highlighting broad accessibility.

• Strategic pipeline prioritization led to pausing enrollment in certain clinical trials and the shutdown of ActoBio operations.

Financial highlights

• Q1 2026 net product revenue for PAPZIMEOS was $21.6 million, driving total Q1 2026 revenue to $23.3 million, up from $1.3 million in Q1 2025.

• Net loss for Q1 2026 was $7.9 million ($0.02 per share), a significant improvement from $54.2 million ($0.18 per share) in Q1 2025.

• R&D expenses were $5.6 million, down $4.8 million year-over-year, while SG&A expenses rose to $21 million, up $8.7 million due to commercialization.

• Cash, cash equivalents, and investments totaled $56.7 million as of March 31, 2026, with Q1 cash used in operations at $43.8 million, including $13 million in non-recurring outflows.

• Long-term debt stood at $93.5 million, with an effective interest rate of 12.5%.

Outlook and guidance

• Expectation of continued revenue acceleration and account activation into Q2 and beyond, with strong payer coverage and community uptake.

• Cash position and receivables projected to fund operations through cash flow break-even by end of 2026; no need for additional capital markets funding anticipated.

• Management believes current liquidity and anticipated PAPZIMEOS revenue will fund operations for at least one year.

• Additional investments planned for clinical and pre-clinical pipeline progression.

• No specific Q2 guidance provided, but management highlights ongoing expansion and momentum.